Grants and Contributions:
Title:
New Ig-Sequencing platform to support the commercialization of REpAb polyclonal sequencing service
Agreement Number:
977520
Agreement Value:
$247,500.00
Agreement Date:
Aug 2, 2021 - Jun 30, 2022
Description:
We will develop and implement a new in-house Ig-Sequencing platform that can be integrated with our proteomics tools to fully assess immune responses in rabbits. The new platform will enable the commercialization of the REpAb service to deliver antibody sequence data that helps customers expedite therapeutic development.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Kitchener, Ontario, CA N2G 4X8
Reference Number:
172-2021-2022-Q2-977520
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
804554392
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by -92 days. The total amended value is -2,000 dollars.
Amendment Date
Oct 21, 2021
Recipient's Legal Name:
Rapid Novor Inc.
Federal Riding Name:
Kitchener Centre
Federal Riding Number:
35045
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171
Amendments: